It has achieved modest protection in phase III trials that correlate with anti-CSP-antibody titers and with CD4+ T cell responses3,4—evidence that antibodies against sporozoite antigens can afford protection against malaria in humans. This evidence concerns the gene DNAJC5 and malaria.